Nyxoah מודיעה על חילופי מנהל הכספים הראשי
מון-סן-גיבר, בלגיה – 21 בספטמבר 2026, GLOBE
NEWSWIRE:
Nyxoah SA (נאסד"ק/יורונקסט בריסל: NYXH), חברת טכנולוגיות רפואיות המתמקדת בפיתוח פתרונות חדשניים לטיפול בדום נשימה חסימתי בשינה (OSA), באמצעות
נוירומודולציה, הודיעה היום כי
ג'ון לנדרי, מנהל הכספים הראשי של החברה, יסיים את תפקידו ב-2 באוקטובר 2026 לטובת
הזדמנות מקצועית אחרת. לואיק מורו, נשיא הפעילות הבינלאומית של החברה וסמנכ"ל
הכספים לשעבר, ישמש כמנהל הכספים הראשי בפועל החל ממועד עזיבתו של לנדרי, וזאת
במקביל לתהליך איתור מחליף קבוע שמנהלת החברה.
Nyxoah Announces Chief Financial Officer
Transition
Loïc Moreau, Nyxoah’s President International
and former CFO, to serve as interim CFO
Company reaffirms full year 2026 financial
guidance
Mont-Saint-Guibert, Belgium – September 21, 2026, GLOBE NEWSWIRE –
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)
(“Nyxoah” or the “Company”), a medical technology company that develops
breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through
neuromodulation, today announced that John Landry, Chief Financial Officer,
will step down from his role effective October 2, 2026 to pursue another
professional opportunity. Loïc Moreau, the Company’s President International
and former CFO, will serve as Interim CFO effective upon Mr. Landry’s departure
while the Company conducts a search for a permanent successor.
“We are fortunate to have Loïc available to
step into the interim CFO role. He knows this Company deeply, having previously
served as our CFO prior to becoming President International, and that
continuity gives us full confidence in a smooth transition as we continue to
execute on our growth strategy and path to profitability,” commented Olivier
Taelman, Chief Executive Officer. “I want to thank John for his contribution to
Nyxoah and wish him success in his next endeavor.”
Loïc Moreau joined Nyxoah in 2022 as Chief
Financial Officer and transitioned to the role of President International in
2024. He is a seasoned finance leader with more than 20 years of experience,
having held senior roles at GSK, including in M&A/Corporate Development and
as Country CFO across multiple geographies. Prior to GSK, he began his career
in External Audit at EY and in Corporate Finance at PwC.
Reaffirmation of Financial Guidance
Nyxoah is reaffirming the financial guidance
for the full year 2026 that it previously issued:
- The Company expects
worldwide net revenue for the full year 2026 to be in the range of €36
million to €40 million.
- The Company expects
gross margin for the full year 2026 to be in the range of 60% to 62%.
- The Company expects
total operating expenses for the full year 2026 to be in the range of €99
million to €102 million.
- The Company expects
non-GAAP cash operating expenses for the full year 2026 to be in the range
of €88 million to €90 million. Non-GAAP cash operating expenses reflect
expected total operating expenses less non-cash expenses such as
depreciation, amortization, and share-based compensation.
About Nyxoah
Nyxoah is a medical technology company
focused on the development and commercialization of innovative solutions to
treat OSA. Nyxoah’s lead solution is the Genio system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for OSA, the
world’s most common sleep disordered breathing condition that is associated
with increased mortality risk and cardiovascular comorbidities. Nyxoah is
driven by the vision that OSA patients should enjoy restful nights and feel
enabled to live their life to its fullest.
Following the successful completion of the
BLAST OSA study, the Genio system received its European CE Mark in 2019. Nyxoah
completed two successful IPOs: on Euronext Brussels in September 2020 and
NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study,
Nyxoah received CE mark approval for the expansion of its therapeutic
indications to Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company announced
positive outcomes from the DREAM IDE pivotal study in 2024 and received
approval from the FDA in August 2025, with the treatment of CCC patients
included in the warning section of our indications for use.
For more information, please visit http://www.nyxoah.com.
Caution – CE marked since 2019. FDA approved
in August 2025 as prescription-only device.
תגובות
הוסף רשומת תגובה